Navigation Links
Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinson's Disease Under Rapid Response Innovation Awards 2008
Date:7/29/2008

$2 million in total funding expected by year's end

NEW YORK, July 29 /PRNewswire-USNewswire/ -- Gene silencing techniques and induced pluripotent stem cell technology are among the cutting-edge approaches to Parkinson's drug development funded through The Michael J. Fox Foundation's Rapid Response Innovation Awards 2008. As part of its mission to drive transformative treatments and a cure for PD, the Foundation has awarded $1.1 million for 15 high-risk, high-reward Parkinson's disease research projects under the initiative in the first half of the year. Applications are still being accepted, and a total of $2 million in Rapid Response awards is expected by year's end.

Rapid Response helps keep new and novel approaches to Parkinson's disease flowing into the drug development pipeline by allowing researchers to pursue their most exciting ideas in real time. The Foundation accepts Rapid Response proposals on a rolling basis with no deadline, and funding decisions are made within six weeks of application. Awards of up to $75,000 are available for one-year basic, preclinical or clinical research projects in any Parkinson's-relevant arena. The program has met with an enthusiastic response from the research community, both within Parkinson's disease and beyond, since it was first launched in January 2007.

"Rapid Response infuses capital quickly into exciting new ideas that could open up important new avenues of inquiry for Parkinson's disease," said Katie Hood, CEO of The Michael J. Fox Foundation. "Our goal is to provide the funding needed to further 'build the case' for these new concepts, developing the data required before other traditional funding sources can step in."

The program's application process and funding criteria emphasize speed and novelty. Funded projects typically are strong ideas being tested for the first time. Unlike other Foundation initiatives, Rapid Response allows for the submission of applications at any time of
'/>"/>

SOURCE Michael J. Fox Foundation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
2. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
3. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
4. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
5. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
6. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
7. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
8. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
9. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
10. Kevin McHale Instrumental in Forming the Help Me Hear Foundation
11. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...wire-FirstCall/--Pharmasset,Inc.(Nasdaq: VRUS ),ac...ering,developingandcommercializingnoveldrugstotrea...calyearendedSeptember30,2009.AtSeptember30,2009Pha...ortterminvestments. ,, PipelineUpdateand2009Hi..., InlateNovember2009,anindependentDataMonitoring...
(Date:11/25/2009)...--BioTrendsResearchGroup,Inc.releasedWave1ofits L...ti-phasesyndicatedmarketresearchprojecttrackingthe...launchthroughthefirstsixmonthsofavailability.Eachw...5uniqueDermatologistsandqualitativeinformationfrom...bstaclestouse,typicalpatienttypes,productperceptio...
(Date:11/25/2009)...swire-USNewswire/--RemediumTechnologiesInc.,acompa...leeding,wonfirstprizeand$10,000intheMostPromisingS...9,companyofficialsannouncetoday. ,, Selectedfro...ampitchedtheirinventionattheGSCSecuritySummitconfe...um( www.remediumtechnologies.com )isdevelopingahig...
Breaking Medicine Technology:Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3BioFlu Could This Be The Natural Defence Against Swine Flu 3F 54947 1BioFlu Could This Be The Natural Defence Against Swine Flu 3F 54947 2BioFlu Could This Be The Natural Defence Against Swine Flu 3F 54947 3Synthesis and Purification of Peptide Libraries Innovative Approaches 13634 1Synthesis and Purification of Peptide Libraries Innovative Approaches 13634 2Florida Spine Surgeon Alfred Bonati M D Announces Results of National Poll Showing America 26apos 3Bs Doctors Oppose a Government Run Health Care Pl 54942 1Florida Spine Surgeon Alfred Bonati M D Announces Results of National Poll Showing America 26apos 3Bs Doctors Oppose a Government Run Health Care Pl 54942 2
... NEW YORK--(BUSINESS WIRE)--Apr 4, 2007 - ImClone ...ers Squibb Company (NYSE:,BMY) announced today tha...ximab) combined with platinum-based chemotherapy,m...ival in patients,with recurrent and/or metastatic ...N). The randomized, multi-center study, known as,E...
... COLLEGEVILLE, Pa., April 03, 2007 /PRNewswire-Fi...yeth , provides comment on a,re- analysis of poole...,s Health Initiative (WHI) Study published today i... The pooled analysis,showed no apparent increase i...rmone therapy close to menopause. , The publicatio...
Other Medicine Technology:Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 2Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 3Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 4Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 5Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 6Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 7Survival Data Available from Erbitux Study in First-Line Treatment,of Advanced Head and Neck Cancer 8New Analysis of Data from WHI Provides Reassurance With Respect to,Coronary Heart Disease For Newly Menopausal Women Considering,Hormone Therapy 2New Analysis of Data from WHI Provides Reassurance With Respect to,Coronary Heart Disease For Newly Menopausal Women Considering,Hormone Therapy 3New Analysis of Data from WHI Provides Reassurance With Respect to,Coronary Heart Disease For Newly Menopausal Women Considering,Hormone Therapy 4New Analysis of Data from WHI Provides Reassurance With Respect to,Coronary Heart Disease For Newly Menopausal Women Considering,Hormone Therapy 5New Analysis of Data from WHI Provides Reassurance With Respect to,Coronary Heart Disease For Newly Menopausal Women Considering,Hormone Therapy 6
(Date:11/25/2009)...RONTOandCALGARY,Nov.25/PRNewswire/-SentinelleMedic...ing(MRI)coilsandsoftwareandCalgaryScientificInc.,a...introducedawebversionofAegis(TM)Breast4DAdvancedVi...isthefirsttrulyzero-footprintWebclientbasedmedical...Web(TM)platformallowsforzero-footprintaccess-requi...
(Date:11/25/2009)...LVERSPRING,Md.,Nov.25/PRNewswire-USNewswire/--Anar...forDrugEvaluationandResearch,titled"ADifficultBala...theNov.26,2009issueofTheNewEnglandJournalofMedicin...h/20090824/FDALOGO ) ,, Inthearticle,Woodcockdi...inmedicationforthosewhoneeditandmanagingtheriskspo...
(Date:11/25/2009)...roadPoliticalEndorsements,Business,andPressJoinEff...e-USNewswire/--Onceagain,theNationalBipolarFoundat...ndorsingtheir"Safe,tilStable"program,whichisnowbei...ipolardisorder.Today,theNationalBipolarFoundationr...PriorityMailfromtheLt.GovernorofLouisianaMitchLand...
(Date:11/25/2009)...uitous discovery that grew out of a collaboration ...ially offer hope to the nearly 10 million American... , Also known as hardening of the arteries, peri...latory problem in which narrowed arteries reduce b...d a red flag for vascular disease, heart attack an...
(Date:11/25/2009)... already used to fight rheumatoid arthritis, could... , WEDNESDAY, Nov. 25 (HealthDay News) -- A ... and rheumatoid arthritis now also shows some prom...1 diabetes. , The drug, rituximab (Rituxan), he...ulin, even though the disease had destroyed some o...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3
...acid supplements may slow cognitive decline in som... do not appear// to affect those with more advance... Alzheimer’s disease is a severely debilitati... according to background information in the articl...
... the ruling by Maryland's highest court a group of... state's medical// assistance program by Republica...The Court of Appeals voted unanimously that Ehrlic...ldren and pregnant women who were recent but legal...
...strict the use animals for the purpose of drug tes... are being developed by researchers at the Univers...130,000? as a financial grant. Gauging the ca...ety. Gentronix , a research company founded by ...
... a decline in the incidence of stroke in Perth, We...ding to new research// announced today by The Geor...l Scientific Meeting of the Stroke Society of Aust...tionally, over 53,000 strokes occur each year, of ...
...are provided by doctors and dentists according to ... which runs Barrowa€?s Furness General Hospital is...re Commission has roundly criticised the NHS servi...erformance of NHS in relation to government target...
...ut down the neo-natal intensive care unit of the R...immediate //effect was passed by the Philippine He...ts of the death of seven new born babies. Th...-natal sepsis”. . An inspection control commi...
Other Medicine News:Health News:Omega-3 May Slow Cognitive Decline in Some with Very Mild Alzheimer’ 2Health News:Health Care Benefits for Immigrants Favored by MD Court 2Health News:Grant Encourages Drug Testing Sans Animals 2Health News:Declining Incidence of stroke in Australia 2
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
...national reference laboratory and a worldwide lead...nt. ARUP offers an extensive test menu of highly c...atomic pathology. Owned by the University of Utah,... of the nation's university teaching hospitals and...
Medicine Products: